Physician profile
Ashima Agarwal
NPI 1114171915
$4,868.31
in general payments reported to CMS, 2019-2025
28 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 89% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2021: $122 · 2022: $630 · 2023: $1,120 · 2024: $875 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $613.35 | 2022-2024 | Korlym |
| Novo Nordisk INC | $599.75 | 2021-2025 | Ozempic, Wegovy |
| Abbott Laboratories | $449.32 | 2019-2023 | Perclose Prostyle |
| Astrazeneca Pharmaceuticals Lp | $413.41 | 2019-2023 | Farxiga |
| Medtronic, INC. | $385.26 | 2023-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $245.45 | 2024-2025 | |
| Insulet Corporation | $237.55 | 2024-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $226.04 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $202.23 | 2023-2024 | |
| Amgen INC. | $163.31 | 2019-2025 | Evenity |
| Sequel Med Tech, LLC | $149.27 | 2025 | Twiist |
| Beta Bionics, INC. | $136.24 | 2024 | Ilet Bionic Pancreas |
| Nestle Healthcare Nutrition INC. | $124.99 | 2023 | |
| Nevro Corp. | $118.63 | 2022 | |
| Aimmune Therapeutics, INC. | $116.33 | 2025 | Zenpep |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.49 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $104.32 | 2025 | |
| Horizon Therapeutics Plc | $97.69 | 2022 | |
| Gt Medical Technologies, INC | $74.12 | 2022-2025 | Gammatile |
| Janssen Biotech, INC. | $70.03 | 2019-2025 | Darzalex, Rybrevant, Talvey |
| Lilly USA, LLC | $69.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $38.67 | 2024-2025 | Libtayo |
| Biosense Webster, INC. | $33.99 | 2025 | Carto 3 |
| Novocure INC. | $25.43 | 2024 | Optune |
| Daiichi Sankyo INC. | $21.70 | 2023 | |
| Mannkind Corporation | $20.83 | 2024 | |
| Genentech USA, INC. | $13.37 | 2019 | |
| Mirati Therapeutics, INC. | $13.32 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashima Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.